Board Change
Summary by AI BETAClose X
10 September 2026
Futura Medical plc
("Futura" or the "Company")
Board Change
Futura Medical plc (AIM: FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that Roy Davis has informed the Company of his decision to step down from his role as Non-Executive Director with effect from 20th October 2026.
Roy’s decision follows a review of his wider board commitments and the time required to fulfil them. With a number of other board responsibilities, Roy has concluded that this is the appropriate time to step down from the Futura Board. His decision is unrelated to the Company’s business, performance or prospects, and he remains strongly supportive of Futura and its current strategy.
Following Roy's departure, the Board will consist of Andrew Unitt (Chair), Alexander Duggan (Chief Executive Officer), Angela Hildreth (COO and Finance Director) and Ken James (Head of R&D). The board has given careful consideration to its composition and, given the Company's current position, the Board does not intend to appoint a replacement Non-Executive Director at this time. The Board will monitor its composition and governance requirements carefully.
Andrew Unitt, Chair of Futura, commented:
"On behalf of the Board, I would like to thank Roy for his outstanding contribution to Futura. His experience, insight and advice have been invaluable during an important period in the Company's development. While we are sorry to see him step down, we fully understand his decision as part of a long-planned review of his wider board and time commitments, and we are pleased that he remains strongly supportive of Futura."
Contacts:
|
Futura Medical plc
|
Alexander Duggan Chief Executive Officer Angela Hildreth Finance Director and COO
|
investor.relations@futuramedical.com +44 (0)1483 685 670
|
|
Panmure Liberum Nominated Adviser and Joint Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
|
+44 (0) 20 3100 2000
|
|
|
|
|
|
Turner Pope Investments (TPI) Ltd - Joint Broker and Retail Offer Coordinator |
Guy McDougall, Andrew Thacker |
+44 (0) 20 3657 0050 |
|
|
|
|
|
Alma Strategic Communications |
Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters |
+44 (0) 20 3405 0205 futura@almastrategic.com |
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative, consumer-focused, sexual health products, including lead product Eroxon® and development projects WSD4000 and Eroxon® Intense. Our core strength lies in our research, development, regulatory and business development expertise in developing innovative, clinically proven, insight-led and effective products to support our customers in the growing sexual health market.
Sexual health issues are prevalent globally in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. 60% of women experience at least one symptom of impaired sexual response or function in a twelve-month period, with only one in four women seeking professional help and remaining chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection fast, addresses significant unmet needs in the ED market. Multiple license or distribution partnerships are in place for Eroxon®, across major consumer markets.
WSD4000 is a project name for Futura's development female sexual health portfolio, starting with the creation of a range of topical gels under Futura's unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication, ability to orgasm and overall sexual satisfaction.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund